Immune checkpoint inhibitors (ICI), including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), and programmed cell death ligand-1 (PD-L1) antibodies, are arguably the most important development in cancer therapy in the past decade. This evidence concerns the gene CTLA4 and cancer.